PT  - JOURNAL ARTICLE
AU  - Gupta, Nivedita
AU  - Kaur, Harmanmeet
AU  - Yadav, Pragya
AU  - Mukhopadhyay, Labanya
AU  - Sahay, Rima R
AU  - Kumar, Abhinendra
AU  - Nyayanit, Dimpal A.
AU  - Shete, Anita M.
AU  - Patil, Savita
AU  - Majumdar, Triparna
AU  - Rana, Salaj
AU  - Gupta, Swati
AU  - Narayan, Jitender
AU  - Vijay, Neetu
AU  - Barde, Pradip
AU  - Natrajan, Gita
AU  - Kumari, B Amurtha
AU  - Kumari, Manasa P
AU  - Biswas, Debasis
AU  - Iravane, Jyoti
AU  - Raut, Sharmila
AU  - Dutta, Shanta
AU  - Devi, Sulochana
AU  - Barua, Purnima
AU  - Gupta, Piyali
AU  - Borkakoty, Biswa
AU  - Kalita, Deepjyoti
AU  - Dhingra, Kanwardeep
AU  - Fomda, Bashir
AU  - Joshi, Yash
AU  - Goyal, Kapil
AU  - John, Reena
AU  - Ashok,
AU  - Dhodapkar, Rahul
AU  - Pandit, Priyanka
AU  - Devi, Sarada
AU  - Dudhmal, Manisha
AU  - Kinariwala, Deepa
AU  - Khandelwal, Neeta
AU  - Tiwari, Yogendra Kumar
AU  - Khatri, PK
AU  - Gupta, Anjali
AU  - Khatri, Himanshu
AU  - Malhotra, Bharti
AU  - Nagasundaram, Mythily
AU  - Dar, Lalit
AU  - Sheikh, Nazira
AU  - Aggarwal, Neeraj
AU  - Abraham, Priya
TI  - Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India
AID  - 10.1101/2021.07.13.21260273
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.13.21260273
4099  - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21260273.short
4100  - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21260273.full
AB  - During March to June 2021 India has experienced a deadly second wave of COVID-19 with an increased number of post-vaccination breakthrough infections reported across the country. To understand the possible reason of these breakthroughs we collected 677 clinical samples (throat swab/ nasal swabs) of individuals who had received two doses (n=592) and one dose (n=85) of vaccines (Covishield and Covaxin,) and tested positive for COVID-19, from 17 states/Union Territories of country. These cases were telephonically interviewed and clinical data was analyzed. A total of 511 SARS-CoV-2 genomes were recovered with genome coverage of higher than 98% from both the cases. Analysis of both the cases determined that 86.69% (n=443) of them belonged to the Delta variant along with Alpha, Kappa, Delta AY.1 and Delta AY.2. The Delta variant clustered into 4 distinct sub-lineages. Sub-lineage–I had mutations: ORF1ab-A1306S, P2046L, P2287S, V2930L, T3255I, T3446A, G5063S, P5401L, A6319V and N-G215C; Sub-lineage –II : ORF1ab- P309L, A3209V, V3718A, G5063S, P5401L and ORF7a-L116F; Sub-lineage –III : ORF1ab- A3209V, V3718A, T3750I, G5063S, P5401L and Spike-A222V; Sub-lineage –IV ORF1ab- P309L, D2980N, F3138S and spike - K77T. This study indicated that majority of the clinical cases in the breakthrough were infected with the Delta variant and only 9.8% cases required hospitalization while fatality was observed in only 0.4% cases. This clearly suggests that the vaccination does provide reduction in hospital admission and mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThe study was conducted with intramural funding for Molecular epidemiological analysis of SARS-CoV-2 circulating in different regions of India of Indian Council of Medical Research (ICMR), New Delhi provided to ICMR-National Institute of Virology, Pune.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Human Ethics Committee of Indian Council of Medical Research-National Institute of Virology, Pune, India - 411021All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data form this study is available with the corresponding author on request.